Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J L Harousseau
Phase I Study of the Anti Insulin-Like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent and in Combination With Bortezomib in Patients With Relapsed Multiple Myeloma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Improvement of Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents: A Three-Decade Experience of a Single Institution
Bone Marrow Transplantation
Transplantation
Hematology
Related publications
A Humanised Anti-Igf-1r Monoclonal Antibody (AVE1642) Enhances Bortezomib-Induced Apoptosis in Myeloma Cells Lacking CD45
British Journal of Cancer
Cancer Research
Oncology
Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis
PLoS ONE
Multidisciplinary
Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison
European Journal of Haematology
Medicine
Hematology
Phase 1 Trial of Vaccination With Autologous Tumor Cells and Antisense Directed Against the Insulin Growth Factor Type 1 Receptor (IGF-1R AS ODN) in Patients With Recurrent Glioblastoma
JHN Journal
Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-Like Growth Factor I Receptor Monoclonal Antibody
Molecular Cancer Therapeutics
Cancer Research
Oncology
Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Blood Cancer Journal
Oncology
Hematology
